Certara Appoints John Reynders as New Independent Board Member
Rhea-AI Summary
Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed John Reynders, PhD, to its Board of Directors, effective October 15, 2024. Dr. Reynders brings over 25 years of experience in the pharmaceutical and tech industries, with expertise in artificial intelligence, data science, and life science.
Dr. Reynders' career highlights include serving as the founding CIO of Moderna, where he led data-sciences capabilities for mRNA therapy design, and as Chief Data Sciences Officer at Neumora. He has also held executive positions at Alexion Pharmaceuticals, AstraZeneca, Johnson & Johnson, Eli Lilly, and Celera.
Certara's CEO, William F. Feehery, PhD, expressed excitement about the appointment, emphasizing the value Dr. Reynders' expertise will bring to the company's ongoing development of transformational software and services for accelerating new medicines and increasing pharma R&D productivity.
Positive
- Appointment of John Reynders, PhD, an experienced pharmaceutical industry leader, to the Board of Directors
- Dr. Reynders brings expertise in artificial intelligence, data science, and life science
- Potential for enhanced development of transformational software and services in pharma R&D
Negative
- None.
RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024.
“We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara’s Board,” said William F. Feehery, PhD, CEO of Certara. “John’s expertise in artificial intelligence, data science, and life science will provide immense value. We will draw on that expertise as we continue to develop and integrate transformational software and services that accelerate new medicines and increase the productivity of pharma R&D.”
Dr. Reynders has over 25 years of experience in the pharmaceutical and tech industries. He was the founding CIO of Moderna where he led the data-sciences capabilities to design mRNA therapies. Most recently, he was Chief Data Sciences Officer at Neumora, a biotech focused on brain diseases. Before that, he held various executive positions leading data-sciences, informatics, and technology organizations at Alexion Pharmaceuticals, AstraZeneca, Johnson & Johnson, Eli Lilly, and Celera.
“I am pleased to join Certara’s Board of Directors and help build on their unique biosimulation portfolio, scientific expertise, and data assets. They are at the intersection of data and life sciences which is where I’ve spent most of my career,” said Dr. Reynders. “I look forward to working with the other board members and Certara’s leadership team to advance the Company’s next phase of growth.”
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.
Certara Contact:
Sheila Rocchio
sheila.rocchio@certara.com
Media Contact:
Alyssa Horowitz
certara@pancomm.com
FAQ
Who is the new independent board member appointed by Certara (CERT)?
What is John Reynders' background and experience relevant to Certara (CERT)?
How might John Reynders' appointment benefit Certara (CERT)?
When did John Reynders join Certara's (CERT) Board of Directors?
